Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer’s disease (AD) reflecting abnormal tau metabolism in the AD brain. Here the authors demonstrate that CSF p-tau217 shows better performance as an AD biomarker than p-tau181.
Guardado en:
Autores principales: | Shorena Janelidze, Erik Stomrud, Ruben Smith, Sebastian Palmqvist, Niklas Mattsson, David C. Airey, Nicholas K. Proctor, Xiyun Chai, Sergey Shcherbinin, John R. Sims, Gallen Triana-Baltzer, Clara Theunis, Randy Slemmon, Marc Mercken, Hartmuth Kolb, Jeffrey L. Dage, Oskar Hansson |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e021f91d669745fe90cd9b4d834f6303 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Sherif Bayoumy, et al.
Publicado: (2021) -
Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Xue-Ning Shen, et al.
Publicado: (2021) -
MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology
por: Chihiro Sato, et al.
Publicado: (2021) -
Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid, tau, and cognition
por: Nicholas C. Cullen, et al.
Publicado: (2021) -
Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Alberto Lleó, et al.
Publicado: (2021)